BRPI0816406A2 - uso de urato oxidase para o tratamento ou a profilaxia de distúrbios ou sequelas indiretas do coração ocasionadas por eventos isquêmicos ou de reperfusão. - Google Patents

uso de urato oxidase para o tratamento ou a profilaxia de distúrbios ou sequelas indiretas do coração ocasionadas por eventos isquêmicos ou de reperfusão.

Info

Publication number
BRPI0816406A2
BRPI0816406A2 BRPI0816406A BRPI0816406A BRPI0816406A2 BR PI0816406 A2 BRPI0816406 A2 BR PI0816406A2 BR PI0816406 A BRPI0816406 A BR PI0816406A BR PI0816406 A BRPI0816406 A BR PI0816406A BR PI0816406 A2 BRPI0816406 A2 BR PI0816406A2
Authority
BR
Brazil
Prior art keywords
ischemic
prophylaxis
treatment
urate oxidase
heart disorders
Prior art date
Application number
BRPI0816406A
Other languages
English (en)
Inventor
Schaefer Matthias
Linz Wolfgang
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of BRPI0816406A2 publication Critical patent/BRPI0816406A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
BRPI0816406A 2007-09-05 2008-08-20 uso de urato oxidase para o tratamento ou a profilaxia de distúrbios ou sequelas indiretas do coração ocasionadas por eventos isquêmicos ou de reperfusão. BRPI0816406A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291072 2007-09-05
PCT/EP2008/006858 WO2009030373A1 (en) 2007-09-05 2008-08-20 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events

Publications (1)

Publication Number Publication Date
BRPI0816406A2 true BRPI0816406A2 (pt) 2017-05-16

Family

ID=38713162

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816406A BRPI0816406A2 (pt) 2007-09-05 2008-08-20 uso de urato oxidase para o tratamento ou a profilaxia de distúrbios ou sequelas indiretas do coração ocasionadas por eventos isquêmicos ou de reperfusão.

Country Status (22)

Country Link
US (1) US20100266567A1 (pt)
EP (1) EP2197550A1 (pt)
JP (1) JP2011509920A (pt)
KR (1) KR20100053609A (pt)
CN (1) CN101801460A (pt)
AR (1) AR068360A1 (pt)
AU (1) AU2008295145B2 (pt)
BR (1) BRPI0816406A2 (pt)
CA (1) CA2697929A1 (pt)
CL (1) CL2008002623A1 (pt)
CO (1) CO6260090A2 (pt)
IL (1) IL204259A (pt)
MA (1) MA31624B1 (pt)
MX (1) MX2010001976A (pt)
MY (1) MY183770A (pt)
NZ (1) NZ583635A (pt)
PA (1) PA8794801A1 (pt)
PE (1) PE20090642A1 (pt)
TW (1) TW200927929A (pt)
UY (1) UY31320A1 (pt)
WO (1) WO2009030373A1 (pt)
ZA (1) ZA201000774B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114972A (en) * 1990-07-30 1992-05-19 Tsuyoshi Ohnishi Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities
WO2002000210A2 (en) * 2000-06-28 2002-01-03 Merck & Co., Inc. Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
WO2004026118A2 (en) * 2002-09-20 2004-04-01 Oregon Health & Science University Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
BRPI0507026A (pt) * 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof

Also Published As

Publication number Publication date
AU2008295145B2 (en) 2013-12-05
EP2197550A1 (en) 2010-06-23
NZ583635A (en) 2011-06-30
WO2009030373A1 (en) 2009-03-12
JP2011509920A (ja) 2011-03-31
PA8794801A1 (es) 2009-04-23
RU2010112867A (ru) 2011-10-10
TW200927929A (en) 2009-07-01
AU2008295145A1 (en) 2009-03-12
KR20100053609A (ko) 2010-05-20
ZA201000774B (en) 2011-04-28
MA31624B1 (fr) 2010-08-02
CN101801460A (zh) 2010-08-11
PE20090642A1 (es) 2009-06-18
CA2697929A1 (en) 2009-03-12
CL2008002623A1 (es) 2009-01-16
AR068360A1 (es) 2009-11-11
CO6260090A2 (es) 2011-03-22
IL204259A (en) 2013-06-27
US20100266567A1 (en) 2010-10-21
MY183770A (en) 2021-03-12
MX2010001976A (es) 2010-03-10
UY31320A1 (es) 2009-04-30

Similar Documents

Publication Publication Date Title
CL2007003049A1 (es) Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
BRPI0912245A2 (pt) composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
NO20084526L (no) Tienpyrimidiner med MNKL/MNK2 inhiberende aktivitet for farmasøytiske sammensetninger
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
CL2007002974A1 (es) Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
BRPI0918527A2 (pt) compostos para o tratamento de disturbios do cns
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
DK2108260T3 (da) Sammensætning med biocid aktivitet til vandige præparater
BR112012000254A2 (pt) análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
EP2139475A4 (en) USE OF PDE7 INHIBITORS IN THE TREATMENT OF
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
BRPI1011768A8 (pt) agentes para o tratamento e/ou profilaxia de um distúrbio, e de uma doença, composição farmacêutica, kit, derivado de tiazol, composto, combinação, e, uso de um derivado de tiazol
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
IL201322A0 (en) Topical fungicidal agents for treating nail disorders
DK1954251T3 (da) Sammensætning med langvarig frigivelse, som har jernsalt som aktiv bestanddel, fremgangsmåde til fremstilling deraf og anvendelse deraf
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
BRPI0814208A2 (pt) Composição para conferir agentes de benefício a substratos aniônicos, e métodos para seu uso.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]